Credit Suisse’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $7.8M | Buy |
111,280
+3,909
| +4% | +$302K | 0.01% | 1048 |
|
|
2023
Q4 | $8.96M | Sell |
107,371
-5,161
| -5% | -$187K | 0.01% | 978 |
|
|
2023
Q3 | $3.32M | Sell |
112,532
-12,026
| -10% | -$401K | ﹤0.01% | 1522 |
|
|
2023
Q2 | $4.06M | Buy |
124,558
+22,873
| +22% | +$846K | ﹤0.01% | 1470 |
|
|
2023
Q1 | $3.58M | Buy |
101,685
+3,373
| +3% | +$138K | ﹤0.01% | 1526 |
|
|
2022
Q4 | $4.5M | Buy |
98,312
+655
| +0.7% | +$28.2K | ﹤0.01% | 1374 |
|
|
2022
Q3 | $4.73M | Buy |
97,657
+4,155
| +4% | +$200K | 0.01% | 1286 |
|
|
2022
Q2 | $3.67M | Sell |
93,502
-352
| -0.4% | -$14.2K | ﹤0.01% | 1504 |
|
|
2022
Q1 | $3.46M | Buy |
93,854
+7,916
| +9% | +$281K | ﹤0.01% | 1713 |
|
|
2021
Q4 | $3.92M | Sell |
85,938
-645
| -0.7% | -$24.9K | ﹤0.01% | 2228 |
|
|
2021
Q3 | $3.1M | Sell |
86,583
-10,984
| -11% | -$323K | ﹤0.01% | 2465 |
|
|
2021
Q2 | $1.93M | Sell |
97,567
-24,041
| -20% | -$564K | ﹤0.01% | 2894 |
|
|
2021
Q1 | $2.83M | Sell |
121,608
-67,152
| -36% | -$1.43M | ﹤0.01% | 2554 |
|
|
2020
Q4 | $3.92M | Buy |
188,760
+57,787
| +44% | +$1.06M | ﹤0.01% | 2299 |
|
|
2020
Q3 | $2.84M | Buy |
130,973
+45,982
| +54% | +$1.08M | ﹤0.01% | 2175 |
|
|
2020
Q2 | $2M | Buy |
84,991
+58,427
| +220% | +$1.1M | ﹤0.01% | 2384 |
|
|
2020
Q1 | $313K | Sell |
26,564
-8,039
| -23% | -$103K | ﹤0.01% | 3404 |
|
|
2019
Q4 | $368K | Sell |
34,603
-26,490
| -43% | -$272K | ﹤0.01% | 3725 |
|
|
2019
Q3 | $695K | Buy |
61,093
+31,663
| +108% | +$397K | ﹤0.01% | 3237 |
|
|
2019
Q2 | $331K | Sell |
29,430
-1,948
| -6% | -$18.8K | ﹤0.01% | 3638 |
|
|
2019
Q1 | $253K | Buy |
31,378
+7,850
| +33% | +$57.7K | ﹤0.01% | 3679 |
|
|
2018
Q4 | $149K | Buy |
23,528
+5,790
| +33% | +$42.5K | ﹤0.01% | 3720 |
|
|
2018
Q3 | $175K | Sell |
17,738
-13,407
| -43% | -$108K | ﹤0.01% | 3673 |
|
|
2018
Q2 | $259K | Sell |
31,145
-5,871
| -16% | -$48.9K | ﹤0.01% | 3675 |
|
|
2018
Q1 | $266K | Buy |
37,016
+4,887
| +15% | +$41.9K | ﹤0.01% | 3611 |
|
|
2017
Q4 | $262K | Sell |
32,129
-21,981
| -41% | -$250K | ﹤0.01% | 3673 |
|
|
2017
Q3 | $784K | Buy |
54,110
+9,688
| +22% | +$132K | ﹤0.01% | 3270 |
|
|
2017
Q2 | $537K | Buy |
44,422
+14,244
| +47% | +$198K | ﹤0.01% | 3106 |
|
|
2017
Q1 | $388K | Buy |
30,178
+9,699
| +47% | +$113K | ﹤0.01% | 3430 |
|
|
2016
Q4 | $249K | Sell |
20,479
-11,832
| -37% | -$126K | ﹤0.01% | 3733 |
|
|
2016
Q3 | $297K | Buy |
32,311
+9,472
| +41% | +$98.9K | ﹤0.01% | 3658 |
|
|
2016
Q2 | $216K | Sell |
22,839
-5,421
| -19% | -$44.5K | ﹤0.01% | 3837 |
|
|
2016
Q1 | $199K | Sell |
28,260
-17,110
| -38% | -$125K | ﹤0.01% | 3685 |
|
|
2015
Q4 | $475K | Buy |
45,370
+31,879
| +236% | +$313K | ﹤0.01% | 3423 |
|
|
2015
Q3 | $90K | Sell |
13,491
-1,677
| -11% | -$11.4K | ﹤0.01% | 4116 |
|
|
2015
Q2 | $102K | Sell |
15,168
-13,109
| -46% | -$86K | ﹤0.01% | 4386 |
|
|
2015
Q1 | $192K | Sell |
28,277
-5,908
| -17% | -$44.1K | ﹤0.01% | 4098 |
|
|
2014
Q4 | $274K | Sell |
34,185
-31,981
| -48% | -$137K | ﹤0.01% | 4108 |
|
|
2014
Q3 | $233K | Sell |
66,166
-32,379
| -33% | -$136K | ﹤0.01% | 4068 |
|
|
2014
Q2 | $471K | Buy |
98,545
+59,672
| +154% | +$364K | ﹤0.01% | 3864 |
|
|
2014
Q1 | $369K | Sell |
38,873
-45,474
| -54% | -$411K | ﹤0.01% | 3942 |
|
|
2013
Q4 | $548K | Buy |
84,347
+18,770
| +29% | +$123K | ﹤0.01% | 3715 |
|
|
2013
Q3 | $496K | Buy |
+65,577
| New | +$703K | ﹤0.01% | 3499 |
|
Other funds holding CYTK
RI
Credit Suisse's CYTK Position: Q1 2024 in Review
Credit Suisse increased its Cytokinetics (CYTK) stake by 3.6% in Q1 2024, buying an estimated $302K and bringing the position to 111,280 shares worth $7.8M. The position accounts for 0.01% of the portfolio, ranked #1048.
Credit Suisse first reported a position in CYTK in Q3 2013 and has held it in 43 quarters since. The position peaked at $8.96M in Q4 2023. 390 funds tracked by Wall St. Rank hold CYTK as of Q1 2024.
- Credit Suisse held 111,280 shares of Cytokinetics worth $7.8M as of Q1 2024.
- Credit Suisse bought 3,909 Cytokinetics shares in Q1 2024, an estimated $302K.
- Cytokinetics made up 0.01% of Credit Suisse's portfolio in Q1 2024, its #1048 holding.
- Credit Suisse first reported a position in Cytokinetics in Q3 2013 and has held it in 43 quarters since.
- Credit Suisse's Cytokinetics position peaked at $8.96M in Q4 2023.
- 390 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.